PubMed Health⌕ Search

Biomedical subjects

E Kanal

Publications and source records attributed to E Kanal.

75 records · Page 5Linked to original sources

Chronic acquired hepatic failure: MR imaging of the brain at 1.5 T.

The results of MR imaging of the brain at 1.5 T in 42 adults with non-Wilsonian chronic hepatic failure are reported. T1-weighted images demonstrated increased signal in the globus pallidus in 30 patients and in the putamen in 21, while T2-weighted images demonstrated no corresponding alteration in signal intensity. Symmetric low intensity in the central portion of the globus pallidus on spin-density and T2-weighted images in two patients correlated with regions of calcification on CT scans. Increased intensity on T1-weighted images also occurred in the mesencephalon surrounding the red nucleus (17/42) and in the quadrigeminal plate (4/42). Three patients demonstrated increased intensity in the pons on T2-weighted images unassociated with clinical brainstem dysfunction. Increased intensity on T1-weighted images was seen in the anterior pituitary in 28 of 35 patients. Alterations in signal intensity were not demonstrated in the cerebral cortex or cerebellum. MR findings did not correlate with laboratory indices of hepatic or thyroid function, with histologic liver diagnosis, or with neurologic status at the time of MR evaluation. Increased signal intensity in the basal ganglia, pituitary gland, and mesencephalon surrounding the red nuclei is characteristic of chronic hepatocellular dysfunction. Deposition of an as yet unidentified paramagnetic substance or altered intracellular water relaxation associated with the proliferation of astrocyte cytoplasmic organelles is postulated as the likely mechanism for this previously undescribed MR manifestation of chronic acquired hepatic failure.

Brain↗

Multicenter trial of gadoteridol, a nonionic gadolinium chelate, in patients with suspected head and neck pathology.

PURPOSE: To evaluate the safety and efficacy of gadoteridol as an MR contrast agent in patients with suspected head and neck pathology. METHODS: One hundred thirty-three adult patients were studied with MR at 12 clinical trial sites before and after the intravenous administration of 0.10 mmol/kg gadoteridol. After enrollment, patients underwent a complete physical examination. Patient monitoring included vital signs, laboratory tests, and recording of the incidence and duration of adverse events. To evaluate efficacy, postcontrast T1-weighted images were compared with precontrast T1- and T2-weighted images. Investigators having clinical information evaluated 129 studies for efficacy; two readers blinded to clinical information subsequently evaluated 122 studies using the same criteria as the investigators. RESULTS: Eight patients (6.0%) experienced mild adverse events possibly or probably related to contrast administration, all of which resolved without treatment. Two clinically significant laboratory abnormalities considered related or possibly related to the administration of gadoteridol were reported in two patients. Enhancement of pathology was seen in 82.9% of cases evaluated by investigators at the study site and in 78.7% of cases subsequently evaluated by the blinded readers. Postcontrast images were judged by investigators to provide additional diagnostic information over precontrast images in 68.9% of studies. The additional diagnostic information available on postcontrast studies most often consisted of improved visualization of pathology and better definition of lesion borders. The use of this information might have contributed to a change in patient diagnosis in 18.6% of the cases evaluated by the investigators and in 16.4% of the cases reviewed by the blinded readers. CONCLUSIONS: Preliminary results show gadoteridol to be a safe and efficacious contrast agent for enhanced MR study of extracranial and extraspinal head and neck pathology.

Adult↗

Reversible ischemia determined by xenon-enhanced CT after 90 minutes of complete basilar artery occlusion.

Intraarterial thrombolytic therapy decreases mortality in the treatment of acute basilar artery occlusion. An acute decrease in cerebral blood flow (CBF) (<12 mL/100 g per minute) has been reported to invariably result in infarction. We report a case of acute basilar artery occlusion, recanalized within 90 minutes, with reversal of CBF of less than 6 mL/100 g per minute. After reperfusion, areas with persistent CBF of 6 mL/100 g per minute resulted in infarctions on subsequent CT studies. Parenchymal viability is possible after 90 minutes of posterior CBF of 6 mL/100 g per minute.

Acute Disease↗